Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 888 in severe hemophilia A
NCT03370172Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 6
01
Overview
Phase 2, open-label trial of TAK-754 in hemophilia A (2 cohorts), sponsored by Takeda. Primary endpoint: Number of Participants With BAX 888-Related Adverse Events at 6 years. Started Feb 2018; status: completed.
02
Drugs
TAK-754
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03370172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370172.